Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Niagen Bioscience, Inc. (NAGE) had Income from Continuous Operations of $4.13M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$33.84M |
|
$4.13M |
|
$12.13M |
|
$21.70M |
|
$29.75M |
|
$4.09M |
|
$0.34M |
|
$4.42M |
|
$4.42M |
|
$4.13M |
|
|
Income from Continuous Operations |
$4.13M |
$4.13M |
|
$4.13M |
|
$4.09M |
|
$4.29M |
|
79.18M |
|
85.44M |
|
$0.04 |
|
$0.05 |
|
| Balance Sheet Financials | |
$96.81M |
|
$1.32M |
|
$9.60M |
|
$106.41M |
|
$19.92M |
|
-- |
|
$9.95M |
|
$29.87M |
|
$76.53M |
|
$70.87M |
|
$76.53M |
|
79.71M |
|
| Cash Flow Statement Financials | |
$13.50M |
|
$-0.29M |
|
$6.92M |
|
$44.66M |
|
$64.79M |
|
$20.13M |
|
$6.07M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.86 |
|
-- |
|
-- |
|
-- |
|
-- |
|
64.14% |
|
12.07% |
|
12.07% |
|
-- |
|
13.07% |
|
12.21% |
|
$13.21M |
|
-- |
|
-- |
|
-- |
|
0.32 |
|
0.59 |
|
3.47 |
|
25.91 |
|
5.40% |
|
5.83% |
|
3.88% |
|
5.40% |
|
$0.96 |
|
$0.15 |
|
$0.16 |
|